Free Trial

Unicycive Therapeutics (UNCY) Competitors

Unicycive Therapeutics logo
$5.00 +0.29 (+6.16%)
Closing price 10/20/2025 04:00 PM Eastern
Extended Trading
$5.03 +0.03 (+0.60%)
As of 10/20/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UNCY vs. MREO, NMRA, ALEC, GALT, SCPH, TECX, ACB, JBIO, IMMP, and KYTX

Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Mereo BioPharma Group (MREO), Neumora Therapeutics (NMRA), Alector (ALEC), Galectin Therapeutics (GALT), scPharmaceuticals (SCPH), Tectonic Therapeutic (TECX), Aurora Cannabis (ACB), Jade Biosciences (JBIO), Prima BioMed (IMMP), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry.

Unicycive Therapeutics vs. Its Competitors

Unicycive Therapeutics (NASDAQ:UNCY) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for Mereo BioPharma Group and 1 mentions for Unicycive Therapeutics. Mereo BioPharma Group's average media sentiment score of 0.43 beat Unicycive Therapeutics' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mereo BioPharma Group
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Mereo BioPharma Group's return on equity of -80.00% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Unicycive TherapeuticsN/A -243.13% -119.46%
Mereo BioPharma Group N/A -80.00%-66.94%

Unicycive Therapeutics currently has a consensus target price of $57.00, suggesting a potential upside of 1,040.00%. Mereo BioPharma Group has a consensus target price of $7.40, suggesting a potential upside of 230.36%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Unicycive Therapeutics is more favorable than Mereo BioPharma Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Mereo BioPharma Group
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.57

Unicycive Therapeutics has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unicycive TherapeuticsN/AN/A-$36.73M-$4.12-1.21
Mereo BioPharma Group$10M35.62-$43.25M-$0.07-32.00

Unicycive Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Mereo BioPharma Group beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UNCY vs. The Competition

MetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$83.19M$2.64B$6.14B$10.55B
Dividend YieldN/A57.79%5.72%4.84%
P/E Ratio-1.2123.8629.4727.34
Price / SalesN/A726.44567.66227.59
Price / CashN/A27.2425.8230.35
Price / Book6.945.4612.436.69
Net Income-$36.73M$33.06M$3.32B$276.46M
7 Day Performance9.65%1.45%1.84%-0.08%
1 Month Performance26.26%10.14%8.84%3.93%
1 Year Performance15.02%-2.58%63.12%33.89%

Unicycive Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UNCY
Unicycive Therapeutics
2.6728 of 5 stars
$5.00
+6.2%
$57.00
+1,040.0%
+16.6%$83.19MN/A-1.219
MREO
Mereo BioPharma Group
1.9957 of 5 stars
$2.00
+2.0%
$7.40
+270.0%
-51.5%$311.64M$10M-28.5740
NMRA
Neumora Therapeutics
2.0193 of 5 stars
$1.86
-1.6%
$7.14
+284.0%
-89.0%$306.08MN/A-1.18108
ALEC
Alector
4.065 of 5 stars
$3.04
+0.7%
$4.17
+37.1%
-33.7%$305.66M$100.56M-2.62270Positive News
GALT
Galectin Therapeutics
1.2772 of 5 stars
$5.10
+8.1%
$6.00
+17.6%
+90.6%$302.36MN/A-7.979News Coverage
Gap Up
SCPH
scPharmaceuticals
3.7804 of 5 stars
$5.67
flat
$7.78
+37.3%
N/A$302.20M$49.97M-3.1330
TECX
Tectonic Therapeutic
2.3379 of 5 stars
$16.09
+0.4%
$80.29
+399.0%
-49.1%$299.77MN/A-3.98120News Coverage
Analyst Forecast
ACB
Aurora Cannabis
0.5431 of 5 stars
$5.40
+1.9%
N/A-4.7%$297.98M$246.72M-28.421,130
JBIO
Jade Biosciences
2.0202 of 5 stars
$9.09
+0.1%
$19.00
+109.0%
N/A$296.25MN/A-0.3020Gap Down
IMMP
Prima BioMed
0.7316 of 5 stars
$1.99
-1.0%
$7.00
+251.8%
+2.5%$295.86M$6.69M0.002,021News Coverage
KYTX
Kyverna Therapeutics
2.3721 of 5 stars
$6.93
+4.5%
$19.00
+174.2%
+33.0%$286.72M$7.03M-1.8896Gap Up

Related Companies and Tools


This page (NASDAQ:UNCY) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners